Initial Experience of Clinical Use of [<sup>99m</sup>Tc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study
Numerous different molecules of prostate-specific membrane antigen (PSMA) ligands are used to detect prostate cancer (PCa); most approaches utilize gallium PET and a few reports describe the role of SPECT/CT. [<sup>99m</sup>Tc]Tc-PSMA-T4 is a new radiopharmaceutical designed for the diag...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/14/11/1107 |
| _version_ | 1827675745538801664 |
|---|---|
| author | Jarosław B. Ćwikła Marek Roslan Iwona Skoneczna Monika Kempińska-Wróbel Michał Maurin Wojciech Rogowski Barbara Janota Anna Szarowicz Piotr Garnuszek |
| author_facet | Jarosław B. Ćwikła Marek Roslan Iwona Skoneczna Monika Kempińska-Wróbel Michał Maurin Wojciech Rogowski Barbara Janota Anna Szarowicz Piotr Garnuszek |
| author_sort | Jarosław B. Ćwikła |
| collection | DOAJ |
| description | Numerous different molecules of prostate-specific membrane antigen (PSMA) ligands are used to detect prostate cancer (PCa); most approaches utilize gallium PET and a few reports describe the role of SPECT/CT. [<sup>99m</sup>Tc]Tc-PSMA-T4 is a new radiopharmaceutical designed for the diagnosis of patients with PCa. We conducted a single site, prospective, preliminary case series study that included 31 patients with PCa; all had undergone clinical, biochemical or imaging examination and exhibited clear or suspicious active disease or clinical/biochemical recurrence of PCa. Whole-body (WB) SPECT/CT after i.v. administration of [<sup>99m</sup>Tc]Tc-PSMA-T4 was utilized; acquisition images were obtained at three time points. The clinical value of the images was assessed in regard to the evaluation of tumor extent in patients with confirmed PC that qualified for initial therapy and the evaluation of tumor recurrence; both provided encouraging results. The late acquisition of WB-SPECT resulted in better lesions delineation. The results of the analysis of the sensitivity/specificity were: 92%/100% in cases of primary cancer, 83%/100% in terms of pelvic lymph nodes disease, 100%/95% in other lymph nodes and soft tissue involvement, respectively, and bone mets were both 100%. An oncotropic SPECT [<sup>99m</sup>Tc]Tc-PSMA-T4 can help in selecting a rational therapeutic strategy for a patient with an initial diagnosis of PCa by assessing the extent of cancer and also after complex radical or palliative therapy in case of biochemical recurrence for re-staging. |
| first_indexed | 2024-03-10T05:10:12Z |
| format | Article |
| id | doaj.art-a0e5ca092f78461a9d09f2c9eaa41c14 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-10T05:10:12Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-a0e5ca092f78461a9d09f2c9eaa41c142023-11-23T00:55:20ZengMDPI AGPharmaceuticals1424-82472021-10-011411110710.3390/ph14111107Initial Experience of Clinical Use of [<sup>99m</sup>Tc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot StudyJarosław B. Ćwikła0Marek Roslan1Iwona Skoneczna2Monika Kempińska-Wróbel3Michał Maurin4Wojciech Rogowski5Barbara Janota6Anna Szarowicz7Piotr Garnuszek8Department of Cardiology and Internal Medicine, School of Medicine, University of Warmia and Mazury, 11-041 Olsztyn, PolandDepartment of Urology, School of Medicine, University of Warmia and Mazury, 11-041 Olsztyn, PolandDepartment of Urology, Grochowski Hospital, 04-073 Warsaw, PolandDepartment of Cardiology and Internal Medicine, School of Medicine, University of Warmia and Mazury, 11-041 Olsztyn, PolandNational Centre for Nuclear Research, Radioisotope Centre POLATOM, 05-400 Otwock, PolandDepartment of Urology, Hospital Ministry of Internal Affairs, 02-507 Warsaw, PolandNational Centre for Nuclear Research, Radioisotope Centre POLATOM, 05-400 Otwock, PolandGE Healthcare, 02-583 Warsaw, PolandNational Centre for Nuclear Research, Radioisotope Centre POLATOM, 05-400 Otwock, PolandNumerous different molecules of prostate-specific membrane antigen (PSMA) ligands are used to detect prostate cancer (PCa); most approaches utilize gallium PET and a few reports describe the role of SPECT/CT. [<sup>99m</sup>Tc]Tc-PSMA-T4 is a new radiopharmaceutical designed for the diagnosis of patients with PCa. We conducted a single site, prospective, preliminary case series study that included 31 patients with PCa; all had undergone clinical, biochemical or imaging examination and exhibited clear or suspicious active disease or clinical/biochemical recurrence of PCa. Whole-body (WB) SPECT/CT after i.v. administration of [<sup>99m</sup>Tc]Tc-PSMA-T4 was utilized; acquisition images were obtained at three time points. The clinical value of the images was assessed in regard to the evaluation of tumor extent in patients with confirmed PC that qualified for initial therapy and the evaluation of tumor recurrence; both provided encouraging results. The late acquisition of WB-SPECT resulted in better lesions delineation. The results of the analysis of the sensitivity/specificity were: 92%/100% in cases of primary cancer, 83%/100% in terms of pelvic lymph nodes disease, 100%/95% in other lymph nodes and soft tissue involvement, respectively, and bone mets were both 100%. An oncotropic SPECT [<sup>99m</sup>Tc]Tc-PSMA-T4 can help in selecting a rational therapeutic strategy for a patient with an initial diagnosis of PCa by assessing the extent of cancer and also after complex radical or palliative therapy in case of biochemical recurrence for re-staging.https://www.mdpi.com/1424-8247/14/11/1107prostate cancermolecular imagingprostate specific membrane antigen (PSMA)[<sup>99m</sup>Tc]Tc-PSMA-T4 |
| spellingShingle | Jarosław B. Ćwikła Marek Roslan Iwona Skoneczna Monika Kempińska-Wróbel Michał Maurin Wojciech Rogowski Barbara Janota Anna Szarowicz Piotr Garnuszek Initial Experience of Clinical Use of [<sup>99m</sup>Tc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study Pharmaceuticals prostate cancer molecular imaging prostate specific membrane antigen (PSMA) [<sup>99m</sup>Tc]Tc-PSMA-T4 |
| title | Initial Experience of Clinical Use of [<sup>99m</sup>Tc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study |
| title_full | Initial Experience of Clinical Use of [<sup>99m</sup>Tc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study |
| title_fullStr | Initial Experience of Clinical Use of [<sup>99m</sup>Tc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study |
| title_full_unstemmed | Initial Experience of Clinical Use of [<sup>99m</sup>Tc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study |
| title_short | Initial Experience of Clinical Use of [<sup>99m</sup>Tc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study |
| title_sort | initial experience of clinical use of sup 99m sup tc tc psma t4 in patients with prostate cancer a pilot study |
| topic | prostate cancer molecular imaging prostate specific membrane antigen (PSMA) [<sup>99m</sup>Tc]Tc-PSMA-T4 |
| url | https://www.mdpi.com/1424-8247/14/11/1107 |
| work_keys_str_mv | AT jarosławbcwikła initialexperienceofclinicaluseofsup99msuptctcpsmat4inpatientswithprostatecancerapilotstudy AT marekroslan initialexperienceofclinicaluseofsup99msuptctcpsmat4inpatientswithprostatecancerapilotstudy AT iwonaskoneczna initialexperienceofclinicaluseofsup99msuptctcpsmat4inpatientswithprostatecancerapilotstudy AT monikakempinskawrobel initialexperienceofclinicaluseofsup99msuptctcpsmat4inpatientswithprostatecancerapilotstudy AT michałmaurin initialexperienceofclinicaluseofsup99msuptctcpsmat4inpatientswithprostatecancerapilotstudy AT wojciechrogowski initialexperienceofclinicaluseofsup99msuptctcpsmat4inpatientswithprostatecancerapilotstudy AT barbarajanota initialexperienceofclinicaluseofsup99msuptctcpsmat4inpatientswithprostatecancerapilotstudy AT annaszarowicz initialexperienceofclinicaluseofsup99msuptctcpsmat4inpatientswithprostatecancerapilotstudy AT piotrgarnuszek initialexperienceofclinicaluseofsup99msuptctcpsmat4inpatientswithprostatecancerapilotstudy |